Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 118
- 试验地点
- 23
- 主要终点
- changes in cardiovascular risk from baseline using the Framingham Coronary Heart Disease Score
研究概览
简要总结
This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and initiating first-line TKIs in routine clinical practice in the US. All treatment decisions will be determined at the discretion of the treating physician(s) and data identifying the cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples (collected following 8 hours of fasting) will be collected during standard of care (SOC)/routine office visits. Additional research imaging will be performed and will be reviewed by core imaging laboratory. As the study is collecting data on management of CML, this study will not influence the prescribing or management practices at participating sites.
详细描述
This non-interventional, prospective study will characterize the impact of three approved first and second generation BCR-ABL1 tyrosine kinase inhibitors on cardiovascular and metabolic risk factors in chronic phase CML (CP-CML) patients who are TKI naive and initiating first-line TKIs in routine clinical practice in the US. All treatment decisions will be determined at the discretion of the treating physician(s) and data identifying the cardiovascular and metabolic risk factors will be collected. Additional fasting blood samples (collected following 8 hours of fasting) will be collected during standard of care (SOC)/routine office visits. Additional research imaging will be performed and will be reviewed by core imaging laboratory. As the study is collecting data on management of CML, this study will not influence the prescribing or management practices at participating sites.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years at the time of Ph+ CP-CML diagnosis
- •Newly diagnosed chronic phase of Ph+ CP-CML, confirmed with cytogenetic and/or molecular testing at baseline
- •Treatment-naïve and initiating treatment with dasatinib, imatinib, nilotinib or bosutinib
- •Willingness and ability to comply with routine office visits
排除标准
- •Any other prior or active non-CML active malignancy for which the patient is receiving treatment
- •Participation in a therapeutic clinical trial for CML disease
结局指标
主要结局
changes in cardiovascular risk from baseline using the Framingham Coronary Heart Disease Score
时间窗: up to 24 months
changes in metabolic risk from baseline using metabolic lab values
时间窗: up to 24 months
次要结局
- time to development of clinical outcomes from baseline to time of clinical outcome event based on clinical assessments(up to 24 months)
- echocardiography to assess left ventricular function(up to 24 months)
- urinary protein excretion to assess early vascular endothelial changes(up to 24 months)
- coronary calcium scoring to assess coronary artery narrowing(up to 24 months)
- metabolic labs (Plasma Glucose, HbA1c, Fasting Lipids) for assessing the metabolic disease(up to 24 months)
- safety and tolerability of first-line BCR-ABL TKIs in adults with CP-CML based on the number of treatment-related adverse events collected in the medical records(up to 24 months)
- clinical outcomes as described by the number of deaths from clinical assessments of disease status and mutational analysis(up to 24 months)
- clinical outcomes as described by the major molecular response from clinical assessments of disease status and mutational analysis(up to 24 months)
- clinical outcomes as described by the cytogenetic response from clinical assessments of disease status and mutational analysis(up to 24 months)
- description of treatment patterns based on the number of changes in treatment dosing, interruptions, changes in therapy, duration of therapy and treatment discontinuations through the management of adverse events and comorbid disease(up to 24 months)
- description of the demographic and clinical patient characteristics associated with initial treatment choice and changes of treatment based on the medical records(up to 24 months)
- measurement of serum biomarkers that are predictive of an increased risk for cardiovascular or metabolic disease(up to 24 months)